Neurocrine Biosciences Downgraded by TheStreet to Sell (NBIX)
Neurocrine Biosciences (NASDAQ:NBIX) was downgraded by equities researchers at TheStreet from a “hold” rating to a “sell” rating in a research report issued on Wednesday, Analyst Ratings Network reports.
The analysts wrote, “Neurocrine Biosciences (NBIX) has been downgraded by TheStreet Ratings from hold to sell. The company’s weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity and weak operating cash flow.”
Several other analysts have also recently commented on the stock. Analysts at Oppenheimer raised their price target on shares of Neurocrine Biosciences from $15.00 to $19.00 in a research note on Monday, February 10th. They now have an “outperform” rating on the stock. Separately, analysts at Roth Capital raised their price target on shares of Neurocrine Biosciences from $22.00 to $24.00 in a research note on Friday, February 7th. Finally, analysts at MKM Partners raised their price target on shares of Neurocrine Biosciences from $17.00 to $20.00 in a research note on Friday, February 7th. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $19.90.
Neurocrine Biosciences (NASDAQ:NBIX) traded up 3.85% during mid-day trading on Wednesday, hitting $13.75. The stock had a trading volume of 360,945 shares. Neurocrine Biosciences has a 1-year low of $8.57 and a 1-year high of $20.29. The stock’s 50-day moving average is $16.17 and its 200-day moving average is $13.3. The company’s market cap is $932.2 million.
Neurocrine Biosciences (NASDAQ:NBIX) last released its earnings data on Thursday, February 6th. The company reported ($0.16) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.17) by $0.01. The company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.79 million. During the same quarter in the prior year, the company posted $0.14 earnings per share. The company’s quarterly revenue was down 96.7% on a year-over-year basis. Analysts expect that Neurocrine Biosciences will post $-0.86 EPS for the current fiscal year.
Neurocrine Biosciences, Inc (NASDAQ:NBIX) discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.